Rocket Lab’s Pentagon Payday Can’t Mask the Pain of a 57% Slide

Rocket Lab's record Pentagon contract and growing backlog contrast with a 56% stock plunge, as investors weigh risks from the $8B Iridium acquisition and Neutron rocket delays.

The numbers coming out of Rocket Lab’s Long Beach headquarters are the kind most space companies would kill for. A $266 million contract from the US Space Force. A backlog swelling to $2.2 billion. A launch vehicle, Electron, that signed 36 new missions in the first quarter alone. Yet the stock tells a radically different story, trading at €58.20 after shedding 56.73% from its May peak of €133.80. The gap between operational momentum and market sentiment has rarely been this wide, and it’s forcing investors to decide which version of reality they trust.

A Record Pentagon Deal That Should Have Been a Catalyst

On July 22, 2026, Rocket Lab confirmed a $266 million contract with the US Space Force — the largest launch award in company history. The deal covers twelve suborbital missions from the Pacific Spaceport Complex in Alaska, with options for six more through 2028. Rocket Lab will use its HASTE vehicle, a variant of the Electron designed for hypersonic testing. What was once a series of one-off technology demonstrations has now matured into a recurring, high-volume service for national security programs.

But the market barely flinched. The reason lies in a much bigger transaction that has consumed investor attention and, for now, confidence.

The Iridium Deal That Changed Everything

Late June 2026, Rocket Lab announced an $8 billion cash-and-stock acquisition of Iridium Communications. Within 30 days, the stock had fallen 21.67%. The deal transforms Rocket Lab from a launch-services company into a vertically integrated satellite operator, putting it in direct competition with SpaceX. The logic is compelling: Iridium’s global satellite constellation provides the recurring, high-margin revenue that launch contracts alone cannot deliver. But the execution risk is enormous, and investors are wrestling with the dilution and capital demands of such an ambitious pivot.

The technical picture reflects the strain. The relative strength index sits at 33.2 — deep in oversold territory. The 200-day moving average of €67.37 now towers above the current price, a level the stock hasn’t touched during this correction. Even the recent 3.19% bounce to €58.20 feels tentative, more a reflex than a reversal.

Neutron: The Make-or-Break Catalyst

The real fulcrum for the bull case — and the source of greatest investor anxiety — is the Neutron rocket. Management continues to target a first flight in the fourth quarter of 2026 or early 2027. The company recently completed a successful static-fire test of the vacuum-optimized AVac engine, reducing technical risk on the propulsion side. But public updates on hardware progress have been sparse since January, and the gap between commercial demand — five missions are already booked before the first flight — and visible milestones has made the market jittery.

History offers some perspective. Falcon 9, New Glenn, Vulcan, and Ariane 6 all flew later than originally scheduled. Structural issues, propulsion problems, and supply-chain delays are part of the development cycle for any new orbital-class rocket. Rocket Lab’s situation is less an anomaly than the industry norm. The company also has the financial firepower to absorb delays: more than $2 billion in available liquidity, according to its first-quarter earnings call.

Analyst Optimism vs. Market Skepticism

The divergence between Wall Street and the trading floor is stark. The consensus from analysts surveyed by S&P Global is a "Buy" rating, with not a single sell recommendation. The average price target of €100.50 implies nearly double the current share price. Piper Sandler has taken a more cautious stance, initiating coverage with a "Neutral" rating, while an insider sale and weakness at a major sector competitor have added to the headwinds.

But the broader analyst community sees a disconnect that favors patient investors. Over the past twelve months, Rocket Lab stock is still up 49.23%, a reminder that the long-term trend remains intact even if the short-term trajectory has been brutal.

The Road Ahead

The fourth quarter will be decisive. If Neutron lifts off as planned, Rocket Lab will have proven that its ambitions and operational capabilities are aligned. If it slips, the stock will likely remain trapped between a record backlog and a market that demands proof before it pays up. For now, the company is executing on two fronts simultaneously — building a new rocket while integrating a satellite network — and the market is pricing that complexity at a steep discount. Whether that discount is a buying opportunity or a warning depends entirely on what happens next.